Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
About the study
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Cutaneous Tumor,Malignant Solid Tumor
Age (in years)
18 - 75
Phase
Phase 1
Participants needed
1
Est. Completion Date
May 31, 2024
Treatment type
Interventional
Sponsor
Immorna Biotherapeutics, Inc.
ClinicalTrials.gov identifier
NCT05539157
Study number
2021-JCXH-211-001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?